TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32899902

Group type: EXPERIMENTAL
Intervention: Passive stretching of respiratory muscles after a hot pack
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received a hot pack followed by relaxed passive movements of the shoulder joints
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 30
Study: 35597286

Group type: EXPERIMENTAL
Intervention: Smartphone-guided self-prone positioning intervention
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 293
Study: 32613250

Group type: EXPERIMENTAL
Intervention: Clear aligners
Number of subjects: 110

Group type: COMPARATOR
Intervention: Fixed appliances
Number of subjects: 110
Study: 34896568

Group type: COMPARATOR
Intervention: RE+control (EX+CON)
Number of subjects: 36

Group type: COMPARATOR
Intervention: RE+whey protein (EX+PRO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: RE (EX+CON and EX+PRO pooled)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Whey protein supplementation (PRO and EX+PRO pooled)
Number of subjects: 36
Study: 34175959

Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction (VR‐D)
Number of subjects: 50
Study: 33112250

Group type: EXPERIMENTAL
Intervention: Home-based monitoring (26% of hospitals, 19/73)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Telemonitoring (23% of hospitals, 17/73)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both home-based monitoring and telemonitoring (11% of hospitals, 8/73)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Telemonitoring (2009-2018)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Telemonitoring centers (17 centers)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Telemonitoring (6/17 centers)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Home-based monitoring and telemonitoring
Number of subjects: 57
Study: 32185992

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Western medicine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Chinese patent medicine
Number of subjects: 105
Study: 35139274

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy group
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Placebo-chemotherapy group
Number of subjects: 1174
Study: 33251650

Group type: EXPERIMENTAL
Intervention: Topical sirolimus 0.2% cream plus Pulsed Dye Laser (PDL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) plus placebo
Number of subjects: 15
Study: 33593770

Group type: EXPERIMENTAL
Intervention: BCG immunisation
Number of subjects: 300

Group type: COMPARATOR
Intervention: No BCG immunisation
Number of subjects: 300
Study: 32227216

Group type: EXPERIMENTAL
Intervention: Topiramate (maximum dosage of 300 mg for 13 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 34
Study: 34524150

Group type: EXPERIMENTAL
Intervention: Cogmed RM, adaptive (experimental group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cogmed RM, nonadaptive (active control group)
Number of subjects: 57
Study: 34062731

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) intervention including sourdough bread, chickpeas/hummus, nuts, and pomegranate juice
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional low-fat diet intervention
Number of subjects: 240
Study: 32452118

Group type: EXPERIMENTAL
Intervention: Isorhamnetin administered orally for 21 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isorhamnetin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil administered orally for 21 consecutive days
Number of subjects: 0
Study: 34463762

Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Time in Bed Regularization (TBR)
Number of subjects: 56
Study: 32539534

Group type: EXPERIMENTAL
Intervention: VCCV tokens categorized into VCuCV and VCiCV categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrimination of VCCV tokens from VCuCV and VCiCV tokens
Number of subjects: 0
Study: 32444166

Group type: EXPERIMENTAL
Intervention: Positive reappraisal coping intervention (PRCI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (questionnaires only)
Number of subjects: 75
Study: 36445774

Group type: EXPERIMENTAL
Intervention: PLA/PGA + rhBMP-2
Number of subjects: 24

Group type: COMPARATOR
Intervention: PLA/PGA alone
Number of subjects: 24
Study: 32945055

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS), 1800 pulses/session, ten daily sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study: 32307654

Group type: EXPERIMENTAL
Intervention: Immunotherapy (immune checkpoint inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33917165

Group type: EXPERIMENTAL
Intervention: Green leafy vegetables (GLV) intervention, 1 cooked cup equivalent daily for 4 weeks
Number of subjects: 50
Study: 32740290

Group type: EXPERIMENTAL
Intervention: Wathen1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mayhew1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MCV1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epley1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RTF1RM
Number of subjects: 20
Study: 34475255

Group type: EXPERIMENTAL
Intervention: Endovascular treatment for acute ischemic stroke (AIS)
Number of subjects: 277
Study: 33530034

Group type: EXPERIMENTAL
Intervention: Women with late-onset preeclampsia (DPE)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Women without late-onset preeclampsia (controls)
Number of subjects: 213
Study: 32122621

Group type: EXPERIMENTAL
Intervention: Recession and plication (RP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recession and resection (RR)
Number of subjects: 60
Study: 35960487

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Apremilast
Number of subjects: 1688
Study: 33524489

Group type: EXPERIMENTAL
Intervention: Personal protective equipment without valve
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Personal protective equipment with valve
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no personal protective equipment)
Number of subjects: 48
Study: 36098968

Group type: EXPERIMENTAL
Intervention: Vitamin D3, 2000 IU/d
Number of subjects: 25871

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids, 1 g/d
Number of subjects: 25871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25871
Study: 35691183

Group type: EXPERIMENTAL
Intervention: Arginine (10 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 30
Study: 33308291

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 35798473

Group type: EXPERIMENTAL
Intervention: 2-stent approach
Number of subjects: 653

Group type: COMPARATOR
Intervention: Provisional Stenting (PS)
Number of subjects: 653
Study: 34555839

Group type: EXPERIMENTAL
Intervention: IV cetirizine 10 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: IV diphenhydramine 50 mg
Number of subjects: 34
Study: 35149037

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 289
Study: 33143369

Group type: EXPERIMENTAL
Intervention: fortified sachet with Ca+VitD and milk plus early PT
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo and milk plus early PT
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: fortified sachet with Ca+VitD and milk plus late PT after childbirth
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo and milk plus late PT
Number of subjects: 69
Study: 34054072

Group type: EXPERIMENTAL
Intervention: Carotid and femoral Doppler ultrasound (DUS) in RA patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Carotid and femoral Doppler ultrasound (DUS) in control group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Carotid DUS in RA patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Femoral DUS in RA patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Carotid and femoral DUS after EULAR 1.5 multiplication factor in RA patients
Number of subjects: 35
Study: 32164646

Group type: EXPERIMENTAL
Intervention: Two-stage screening procedure (first-stage via school setting, second-stage with fasting plasma glucose and blood pressure measurements)
Number of subjects: 3153

Group type: EXPERIMENTAL
Intervention: Two-stage screening procedure
Number of subjects: 3153
Study: 35854360

Group type: EXPERIMENTAL
Intervention: Oral fluoroquinolone or trimethoprim-sulfamethoxazole
Number of subjects: 720

Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 720
Study: 33950373

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTXA) with Zinc supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Botulinum Toxin A (BTXA)
Number of subjects: 25
Study: 32334592

Group type: EXPERIMENTAL
Intervention: Twice-daily exenatide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Insulin (aspartate 70/30)
Number of subjects: 66
Study: 36282119

Group type: EXPERIMENTAL
Intervention: Median Cut Hemifield Test (MCHT) using HTC Vive Pro Eye VR headset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Humphrey Visual Field Analyzer (HVFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient satisfaction with VR vision testing
Number of subjects: 0
Study: 34070377

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (nutritional management, physical activity, stress management, cognitive function improvement) for 8 weeks
Number of subjects: 63
Study: 33357505

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 35348111

Group type: EXPERIMENTAL
Intervention: SB12 (300 mg dose via intravenous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eculizumab (RP, 300 mg dose via intravenous infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SB12 and Eculizumab (RP)
Number of subjects: 0
Study: 32918474

Group type: EXPERIMENTAL
Intervention: Extended Early Intervention Service (EIS)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Regular Care (RC)
Number of subjects: 220
Study: 32652987

Group type: EXPERIMENTAL
Intervention: Structured home-based interview with a chronically ill patient
Number of subjects: 317

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 317
Study: 35040072

Group type: EXPERIMENTAL
Intervention: Modified Pilates Exercises (MPE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT)
Number of subjects: 18
Study: 34661623

Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Still image training
Number of subjects: 0
Study: 32948057

Group type: EXPERIMENTAL
Intervention: multi-DNA damage response interference (mDDRi) as maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRINOX treatment
Number of subjects: 0
Study: 34039583

Group type: EXPERIMENTAL
Intervention: Multi-strategy intervention including centralised technical assistance, ongoing consultation, principal's mandated change, identifying and preparing school champions, development of implementation plans, educational outreach visits and provision of educational materials.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multi-strategy intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual support (guidelines for policy development via education department website and telephone support)
Number of subjects: 61
Study: 32814158

Group type: EXPERIMENTAL
Intervention: Follicular phase group
Number of subjects: 73

Group type: COMPARATOR
Intervention: Luteal phase group
Number of subjects: 73
Study: 32500650

Group type: EXPERIMENTAL
Intervention: Screening arm (SA), N = 32,000, PSA screening at 4-year intervals until 2007.
Number of subjects: 5128

Group type: COMPARATOR
Intervention: Control arm (CA), N = 48,458, no PSA screening.
Number of subjects: 5128

Group type: EXPERIMENTAL
Intervention: Generic HRQOL scores
Number of subjects: 5128
Study: 34921796

Group type: EXPERIMENTAL
Intervention: Task-Shared Care (TSC)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Enhanced Specialist Mental Health Care (PSY)
Number of subjects: 324
Study: 33227037

Group type: EXPERIMENTAL
Intervention: VR-enhanced ultrasonography training program
Number of subjects: 101
Study: 35666542

Group type: EXPERIMENTAL
Intervention: Wii Balance Board System (WBBS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Foam Posturography System (FPS)
Number of subjects: 90
Study: 33233945

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 83
Study: 32004775

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) using a new HPLC-MS/MS method for quantifying dolutegravir (DTG), elvitegravir (ELV), rilpivirine (RPV), raltegravir (RAL), raltegravir‐Î²‐D‐glucuronide (RAL‐GLU), darunavir (DRV), and ritonavir (RTV) in human plasma.
Number of subjects: 0
Study: 35395206

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33923171

Group type: EXPERIMENTAL
Intervention: 12 g of mixed soluble and insoluble fiber for 8 weeks
Number of subjects: 14
Study: 32694162

Group type: EXPERIMENTAL
Intervention: Ferric Citrate (2 g three times a day with meals, n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ferrous Sulfate (325 mg three times a day, n=30)
Number of subjects: 60
Study: 35507383

Group type: EXPERIMENTAL
Intervention: 1 dose of dexamethasone (0.6 mg/kg per dose, maximum of 16 mg)
Number of subjects: 308

Group type: COMPARATOR
Intervention: 2 doses of dexamethasone (0.6 mg/kg per dose, maximum of 16 mg)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 1 dose of dexamethasone
Number of subjects: 308

Group type: COMPARATOR
Intervention: 2 doses of dexamethasone
Number of subjects: 308
Study: 32170358

Group type: EXPERIMENTAL
Intervention: Surgeon-defined assessment (SDA) at 10°
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Surgeon-defined assessment (SDA) at 45°
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Surgeon-defined assessment (SDA) at 90°
Number of subjects: 250
Study: 33406241

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with modified risk tobacco product (MRTP) claims
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with descriptors implying reduced harm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with text-only warnings
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with imagery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging marketing appeals
Number of subjects: 10
Study: 36116229

Group type: EXPERIMENTAL
Intervention: TAU + FIBROWALK
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: TAU + MPP
Number of subjects: 330

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 330
Study: 33779288

Group type: EXPERIMENTAL
Intervention: Plasma Kinetic Enucleation of the Prostate (PKEP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both PKEP and HoLEP
Number of subjects: 160

Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 160
Study: 32903201

Group type: EXPERIMENTAL
Intervention: WOC nurse interventions (67.5% of patients treated by WOC nurse)
Number of subjects: 572
Study: 35027161

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 150
Study: 32853559

Group type: EXPERIMENTAL
Intervention: Mifepristone plus misoprostol
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo plus misoprostol
Number of subjects: 711
Study: 35114151

Group type: EXPERIMENTAL
Intervention: Rituximab-containing therapy (with CHOP chemotherapy)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: CHOP chemotherapy only
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Rituximab therapy (in CLL8 trial)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: FC chemotherapy only
Number of subjects: 1068
Study: 32939934

Group type: EXPERIMENTAL
Intervention: Static CAIS (n = 30)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dynamic CAIS (n = 30)
Number of subjects: 30
Study: 32463599

Group type: EXPERIMENTAL
Intervention: HS016
Number of subjects: 136
Study: 34299697

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-usual (TAU)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 177
Study: 32469095

Group type: EXPERIMENTAL
Intervention: Sponsor-provided drugs
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Industry-sponsored trials
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Academic trials
Number of subjects: 345
Study: 34647777

Group type: EXPERIMENTAL
Intervention: Path2Quit
Number of subjects: 119

Group type: COMPARATOR
Intervention: NCI's SmokefreeTXT
Number of subjects: 119
Study: 32385058

Group type: EXPERIMENTAL
Intervention: Home cook intervention package including community-based standardized offline and online health education and salt intake monitoring for 1 year
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1560
Study: 33646918

Group type: EXPERIMENTAL
Intervention: Good sleep condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poor sleep condition
Number of subjects: 0
Study: 33470660

Group type: EXPERIMENTAL
Intervention: Unilateral Biportal Endoscopy (UBE)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Tubular Microendoscopy (TME)
Number of subjects: 154
Study: 32736928

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (40 mg/40 ml) three times a week for 2 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: TURBT and six weekly adjuvant instillations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C
Number of subjects: 120
Study: 36274158

Group type: EXPERIMENTAL
Intervention: 200 mg progesterone daily for 4 days of abstinence
Number of subjects: 39
Study: 34061838

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine adjuvanted with Cationic Adjuvant Formulation (CAF) 01
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine adjuvanted with Alhydrogel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control vaccine (Rabies)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Helminth infection (mono-infection)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Helminth infection (co-infection)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Absence of helminth infection
Number of subjects: 50
Study: 35932186

Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 235
Study: 32635612

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cord blood DHA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cord blood AA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DHA and AA levels
Number of subjects: 90
Study: 35725347

Group type: EXPERIMENTAL
Intervention: Social media intervention group (including VCT services and comprehensive strategies through social media)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (routine voluntary counseling and testing services)
Number of subjects: 315
Study: 34167881

Group type: EXPERIMENTAL
Intervention: Combination supplementation with vitamin B12 and folate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary and supplemental thiamine intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiamine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening protocols
Number of subjects: 0
Study: 34557922

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) with proctored practice
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) with unproctored practice
Number of subjects: 198

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mindfulness practice (frequency of 3 or more days per week)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mindfulness practice (frequency of practice)
Number of subjects: 198
Study: 32858239

Group type: EXPERIMENTAL
Intervention: Polyvalent mechanical bacterial lysates (PMBLs)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32608179

Group type: EXPERIMENTAL
Intervention: Virtual experience intervention before the scan
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no virtual experience)
Number of subjects: 200
Study: 35122992

Group type: EXPERIMENTAL
Intervention: 500 mg of trans-resveratrol per day for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (500 mg wheat flour) for four weeks
Number of subjects: 20
Study: 33587894

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (COMBI-d)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (COMBI-MB)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Dabrafenib plus placebo (COMBI-d)
Number of subjects: 423
Study: 33151315

Group type: EXPERIMENTAL
Intervention: TACE plus ablative therapy (stereotactic body radiation therapy, microwave ablation, radiofrequency ablation)
Number of subjects: 289

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: TACE plus ablative therapy
Number of subjects: 289
Study: 34481561

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 35296398

Group type: EXPERIMENTAL
Intervention: NU-FlexSIV Socket
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ischial Containment (IC) Socket
Number of subjects: 30